Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Identification of a novel epigenetic marker for typical and mosaic presentations of Fragile X syndrome
Ist Teil von
Expert review of molecular diagnostics, 2023-12, Vol.23 (12), p.1273-1281
Ort / Verlag
England
Erscheinungsjahr
2023
Quelle
MEDLINE
Beschreibungen/Notizen
Fragile X syndrome (FXS) is primarily due to CGG repeat expansions in the
gene.
alleles are classified as normal (N), intermediate (I), premutation (PM), and full mutation (FM). FXS patients often carry an FM, but size mosaicism can occur. Additionally, loss of methylation boundary upstream of repeats results in
methylation spreading to
promoter in FXS patients.
This pilot study investigated the methylation boundary and adjacent regions in 66 males with typical and atypical FXS aged 1 to 30 years (10.86 ± 6.48 years). AmplideX
mPCR kit was used to discriminate allele profiles and methylation levels. CpG sites were assessed by pyrosequencing.
40 out of 66 FXS patients (60.6%) showed an exclusive FM (n = 40), whereas the remaining (n = 26) exhibited size mosaicism [10 PM_FM (15.15%); 10 N_FM (15.15%); 2 N_PM_FM (3%)]. Four patients (6.1%) had deletions near repeats. Noteworthy, a CpG within
intron 2 displayed hypomethylation in FXS patients and hypermethylation in controls, demonstrating remarkable specificity, sensitivity, and accuracy when a methylation threshold of 69.5% was applied.
Since intragenic methylation is pivotal in gene regulation, the intronic CpG might be a novel epigenetic biomarker for FXS diagnosis.